The Pharma Letter M&A roundup - October 2023

7 November 2023
merger_acquisition_deal_shutterstock_large

Swiss pharma giant Roche (ROG: SIX) announced the sector's biggest pharma M&A deal in October.

The month also saw two further deals announced by Eli Lilly (NYSE: LLY), making that six M&A deals this year revealed by the US pharma major.

Spending on pharma M&A in 2023 continues to outstrip the previous two years, with Pfizer's (NYSE: PFE) huge acquisition of Seagen (Nasdaq: SGN) making the former company the biggest spender in the sector so far this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical